Summary:
Adenovirus (AdV) infection is an important cause of morbidity and mortality in hematopoietic stem cell transplant (HSCT) recipients. We treated 16 patients with AdV hemorrhagic cystitis (HC) following HSCT with cidofovir (CDV; 1 mg/kg/day, three times weekly for 3 weeks). Patients included 10 males and six females with a median age of 50 years (range 10-62). Two of the 16 patients were unevaluable because of early death from nonadenoviral causes. CDV therapy cleared AdV from urine in 12 of 14 patients (86%). Of 14 patients, 10 (71%) showed clinical improvements in HC. Among 14 patients, seven (50%) had avoided renal damage, the most important CDV toxicity. One patient previously treated with foscarnet for cytomegalovirus (CMV) required hemodialysis, and CDV treatment was discontinued. In another patient, CDV treatment was discontinued because of grade 2 nephrotoxicity. Four patients became positive for CMV antigenemia while being treated with CDV, and two developed herpes simplex virus (HSV) stomatitis while being treated with CDV. CDV proved effective in treating AdV HC in transplant patients. However, CDV at 1 mg/ kg/day given three times weekly failed to prevent breakthrough infection with CMV and HSV in some patients. [1] [2] [3] are emerging as life-threatening complications in hematopoietic stem cell transplant patients. 4 Reported occurrence rates of AdV infection complicating allogeneic hematopoietic stem cell transplantation (HSCT) vary from 5 to 21%, 1, [5] [6] [7] [8] and reported mortality rates have ranged from 7.7 to 38%. 6, [9] [10] [11] For treatment of AdV infection, reduction of immunosuppression 8 or infusion of donor lymphocytes 12 have been proposed. However, since AdV infections often occur in the presence of severe graft-versus-host disease (GVHD), immunotherapy may not be feasible. While specific antiAdV therapy is therefore needed, no presently available drug has been proven to be effective, although some treatment success with ganciclovir (GCV), 13 vidarabine (AraA) 14 and ribavirin 15, 16 have been reported. Unfortunately, these results could not be reproduced. 17 Cidofovir (CDV), a monophosphate nucleotide analogue of cytosine that inhibits viral DNA polymerase, demonstrates in vitro and in vivo activity against several viruses including herpesviruses, AdV, papilloma viruses, polyoma viruses, and poxvirus. 18 Several reports have described the effectiveness of CDV in post-transplant AdV disease. 19, 20 The doselimiting toxicity of intravenous CDV, when given at the recommended dose of 5 mg/kg once weekly, is nephrotoxicity. 18 Recently, a smaller, more frequent dose of CDV, 1 mg/kg/day three times weekly, demonstrated efficacy for treatment of post-transplant AdV infection. 20 In the present study, we have prospectively evaluated both toxicity and efficacy of CDV treatment for AdV HC in transplant patients. In all, 16 transplant patients were treated with CDV at a dose of 1 mg/kg, three times weekly for 3 weeks.
Materials and methods

Diagnosis of AdV HC
To exclude regimen-related HC, only patients who developed macroscopic hematuria with clinical signs of cystitis newly appearing de novo at least 10 days after HSCT and also had no tendency toward generalized bleeding or bacteriuria were considered to have HC. 21 According to previously reported criteria with minor modifications, 22 the severity of HC was graded as mild, sustained microscopic hematuria; moderate, gross hematuria and dysuria without clots; severe, gross hematuria and dysuria with clots. At the onset of HC, a urine specimen was obtained for viral culture and polymerase chain reaction (PCR). For rapid diagnosis, immunochromatography was performed (Adenocheck; Santen, Osaka, Japan). All patients underwent all the three diagnostic modalities (viral culture, PCR, and immunochromatography). When AdV was detected by one or more of these methods, a diagnosis of AdV HC was made.
Viral culture from urine
A 2 ml volume of urine was centrifuged overnight at 20 000 g and the sediment was added to culture of Hep-2 cells for up to 4 weeks. When a cytopathic effect of viral infection was observed, viral species were identified using monoclonal antibodies against AdV. Viral culture was carried out before the initiation of CDV treatment and 1 week after the last dose of CDV. The clearance of AdV was defined as the negative viral culture after treatment.
PCR of urine samples
After 2 ml of a urine sample was centrifuged at 15 000 g for 1 h at 41C, the sediment was resuspended in 100 ml of PBS. DNA was purified using QIAmp DNA Blood Mini Kit (Qiagen, Hilden, Germany). Next, 5 ml of purified DNA was subjected to PCR assay using a GeneAmp Kit and a GeneAmp PCR System 9600 (Perkin-Elmer, Boston, MA, USA). Primers used to screen for AdV infection were AD185S (5 0 -tccagcaacttcatgtccatgg-3 0 ) and AD 185A (5 0 -tcgatgacgccgcggt-3). The size of the final products was confirmed by 3% agarose gel electrophoresis. 21 
Patient characteristics
In total, 16 patients were treated with CDV (10 males and six females with a median age of 50 years, ranging from 10 to 62). All patients had AdV HC. In all, 14 patients underwent allogeneic HSCT for acute myelogenous leukemia (AML) (n ¼ 1), acute lymphoblastic leukemia (ALL) (n ¼ 2), adult T-cell leukemia/lymphoma (ATL) (n ¼ 2), chronic myelogenous leukemia (n ¼ 1), myelodysplastic syndrome (MDS) (n ¼ 1), multiple myeloma (MM) (n ¼ 2), malignant lymphoma (ML) (n ¼ 1), and severe aplastic anemia (SAA) (n ¼ 3). Two other patients with systemic sclerosis underwent CD34 þ cell autologous HSCT. Among allogeneic transplants, sources of stem cells were as follows: three from HLA-identical family donors, one from a DR-mismatch family donor, two from haploidentical family donors, five from unrelated donors, and three from unrelated cord bloods. Patients No. 3 and no. 12 received antithymocyte globulin (ATG) as part of conditioning (Table 1) .
Patient No. 2 died of cerebral infarction 5 days after initiation of CDV treatment, while patient No. 13 died from fungal pneumonia 11 days after initiation of CDV treatment. As these two patients with early death unrelated to AdV were excluded from analysis, 14 patients were evaluable. All patients received immunosuppressive therapy including cyclosporine, tacrolimus, and a steroid, as shown in Table 2 . Serotypes of AdV isolated from urine were type 11 (11 patients), type 35 (one patient), or not determined (two patients). Onset of AdV HC ranged from 17 to 142 days after post transplantation (median, 37). Intervals between the onset of AdV HC and CDV treatment ranged from 0 to 56 days (median, 3). Two patients received AraA for treatment of AdV HC (Table 2) .
CDV treatment
All of the patients gave their written informed consent in accordance with the requirements of the Institutional Review Board. The treatment regimen consisted of CDV, 1 mg/kg per day three times weekly for 3 weeks. Oral Probenecid (2 g) was given 3 h before CDV administration, while 1 g was given 1 and 8 h afterward. Intravenous hydration with normal saline also was given. Patients were followed up for 2 months after the completion of CDV treatment.
Results
Outcome of CDV therapy
CDV therapy was successful in clearing AdV from the urine in 12 of 14 patients (86%), as defined by negative culture for AdV 1 week after the last dose of CDV. Of 14 patients, 10 (71%) showed clinical improvement in HC (Table 3) .
Median time to improvement of HC grade after CDV therapy was 9.5 days (range, 6-14; Table 3 and Figure 1 ). Patients No. 3 and No. 5 had persistent symptoms of HC despite eradication of AdV in the urine.
Toxicity
Serum creatinine concentration for all patients, at the time of initiation and termination of CDV treatment, as well as the maximum serum creatinine concentration during CDV treatment, are shown in Table 3 . Renal toxicity was graded according to the Common Toxcity Criteria of National Cancer Institute (NCI-CTC Version 2.0; April 30, 1999). Among 14 patients, seven (50%) had no renal toxicity. Virally associated findings during the treatment with CDV Table 1 showed donor/recipient CMV and recipient HSV serostatus. As CDV has been reported to have significant anti-CMV and anti-HSV activity, concurrent use of acyclovir (ACV) or GCV was avoided to reduce renal toxicity. Patient No. 5 developed CMV antigenemia when CDV treatment was started, and CMV antigenemia persisted during CDV treatment. After completion of CDV treatment, he was treated with GCV, which abolished CMV antigenemia. Before CDV treatment, patient No. (Table 3) .
Discussion
The present study reports the outcome in AdV HC treated with CDV. As expected, the main toxicity of CDV treatment was renal. Among 14 evaluable patients, two developed severe renal toxicity, resulting in discontinuation of CDV treatment. One of these patients who required hemodialysis had a history of foscarnet treatment. Previous treatment with foscarnet has been reported to exacerbate CDV renal toxicity, 23 which was proved for this patient. CDV renal toxicity complicating treatment of AdV HC is difficult to evaluate. Many other nephrotoxic agents, including cyclosporine, tacrolimus, and amphotericin B, are frequently administered to HSCT patients; furthermore, AdV infection itself can cause renal damage such as nephritis 16 and obstructive nephropathy. 24 In this study, six patients (Nos. 5, 9, 12, 14, 15, and 16) experienced increased level of serum creatinine concentrations, but continued CDV treatment, with improvement in terms of both AdV HC and renal function (Table 3) . Thus, AdV HC itself may have contributed to the increase in serum creatinine during CDV treatment. Use of CDV before emergence of renal damage from AdV infection would be desirable. Patient No. 10 developed VOD, which has not been reported previously as a form of CDV toxicity. More information is necessary to determine whether or not VOD is among CDV toxicities. Among 14 evaluable patients, 10 (71%) showed clinical improvement of AdV HC, which is similar to a success rate of 63% reported in patients with definite AdV disease reported by the European Group for Blood and Marrow Transplantation. 25 A long delay between AdV infection and treatment has been linked to a greater risk of treatment failure. 17 For rapid diagnosis, we used immunochromatography. At the onset of HC, all patients in the study were positive for AdV by this method. Positivity was confirmed later both by PCR result and by isolation of AdV from urine. Thus, immunochromatography appears reliable for rapid diagnosis of AdV HC. Since post-transplant AdV infection causes significant mortality 6,9-11 and HC causes considerable patient discomfort, CDV would appear to be beneficial treatment while maintaining an acceptable toxicity profile.
At a dose of 5 mg/kg/week, CDV has been reported to have significant anti-CMV and anti-HSV activity. 26 Indeed, CDV is considered a second-line treatment for GCVrefractory CMV disease. 27 Among our patients, two had persistent CMV antigenemia and two developed CMV antigenemia during treatment with CDV. In addition, two patients developed HSV-1 stomatitis. Thus, CDV at a dose of 1 mg/kg/day three times weekly may be insufficient to prevent or treat CMV or HSV disease. Alternatively, patients who develop AdV HC might be immune compromised to the extent that for them CDV treatment may not be effective against CMV or HSV. Vigilance against infection by and/or additional prophylaxis agents for herpesviruses, therefore, is important during CDV treatment with 1 mg/kg three times weekly.
In conclusion, CDV at a dose of 1 mg/kg/day, three times weekly could be administered with acceptable toxicity for effective treatment of AdV HC. Prospective randomized trials are necessary to further study the use of CDV for AdV HC.
